Aptevo Therapeutics Inc.APVONASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank92
5Y CAGR+11.8%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+11.8%/yr
Long-term compound
Percentile
P92
Near historical high
vs 5Y Ago
1.7x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 23.05% |
| Q2 2025 | 1.79% |
| Q1 2025 | 13.79% |
| Q4 2024 | 18.58% |
| Q3 2024 | -11.38% |
| Q2 2024 | -26.31% |
| Q1 2024 | 15.68% |
| Q4 2023 | 4.45% |
| Q3 2023 | -1.55% |
| Q2 2023 | -24.30% |
| Q1 2023 | 19.20% |
| Q4 2022 | -8.98% |
| Q3 2022 | -10.55% |
| Q2 2022 | -4.20% |
| Q1 2022 | 22.04% |
| Q4 2021 | -9.11% |
| Q3 2021 | -15.35% |
| Q2 2021 | 4.13% |
| Q1 2021 | -7.78% |
| Q4 2020 | 33.13% |
| Q3 2020 | 13.20% |
| Q2 2020 | -21.46% |
| Q1 2020 | -27.56% |
| Q4 2019 | -22.92% |
| Q3 2019 | -0.95% |
| Q2 2019 | -10.80% |
| Q1 2019 | 11.45% |
| Q4 2018 | -5.23% |
| Q3 2018 | -1.18% |
| Q2 2018 | -7.49% |
| Q1 2018 | -11.28% |
| Q4 2017 | 14.51% |
| Q3 2017 | -14.64% |
| Q2 2017 | -16.99% |
| Q1 2017 | 21.12% |
| Q4 2016 | -25.45% |
| Q3 2016 | 31.86% |
| Q2 2016 | -5.97% |
| Q1 2016 | -33.39% |
| Q4 2015 | 66.12% |